Case Report: Tocilizumab in pediatric febrile infection-related epilepsy syndrome
Lingyu Pang, Xuefang Liu, Suzhen Sun, Fang Chen, Hongru Lu, Yakun Du, Xin Li · 2026
Read Case Report: Tocilizumab in pediatric febrile infection-related epilepsy syndrome by Lingyu Pang, Xuefang Liu, Suzhen Sun, Fang Chen, Hongru Lu, Yakun Du, Xin Li (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13271945.txt.
Description
Lingyu Pang and coauthors describe in 2026 two children with febrile infection-related epilepsy syndrome treated with the immune drug tocilizumab. In this syndrome, healthy children develop nonstop seizures shortly after a feverish illness. Standard seizure drugs often fail, and outcomes can be severe.
Both children showed raised levels of the immune signal IL-6 in blood. One child, treated late on day 58, gained only brief relief and remained severely affected. The second, treated on day 7, stayed seizure free for six months without clear thinking decline. Comparing all reported cases, the authors suggest starting within three weeks may matter most.
Catalog record
| CREATOR | Lingyu Pang, Xuefang Liu, Suzhen Sun, Fang Chen, Hongru Lu, Yakun Du, Xin Li |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 27 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |